Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PCR for monitoring of minimal residual disease in hematologic malignancy.

Clinica chimica acta; international journal of clinical chemistry - 18 Jan 2012

Matsuda Kazuyuki, Sugano Mitsutoshi, Honda Takayuki

Abstract excerpt

Monitoring minimal residual disease (MRD) is useful to evaluate therapeutic response and risk of relapse in patients with hematologic malignancy. Currently available quantitative MRD assays are fluorescence in situ hybridization of chromosomal aberrations; multiparameter flow cytometry of leukemia-associated immunophenotypes; and quantitative polymerase chain reaction (qPCR) analysis of fusion genes,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA, Messenger
Share to Gene Fusion
Share to Genetic Markers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Monitoring, Physiologic

Share to Neoplasm, Residual

Share to Polymerase Chain Reaction

Share to Receptors, Antigen, T-Cell

Source

Identifiers

PMID: 22057038
DOI: 10.1016/j.cca.2011.10.022

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PCR for monitoring of minimal residual disease in hematologic malignancy.PMID 22057038Read ↗

[Evaluation of minimal residual disease using allele (mutation) -specific PCR].Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

Minimal Residual Disease Detection in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.Semantic proximity Read ↗

Quantitative monitoring of single nucleotide mutations by allele-specific quantitative PCR can be used for the assessment of minimal residual disease in patients with hematological malignancies throughout their clinical course.Semantic proximity Read ↗

Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patientSemantic proximity Read ↗

An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read ↗

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.Semantic proximity Read ↗

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Detection and management of minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.